In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other biotech stocks. As we have mentioned in our article, “10 Best Penny Stocks to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gilead Sciences reported good quarterly results and in the last few weeks, the stock rallied higher. Oncology will especially contribute to growth in the years to come, and maybe Gilead Sciences ...

Given the large stake in the stock by institutions, Gilead Sciences' stock price might be vulnerable to their trading decisions The top 15 shareholders own 50% of the company Ownership research ...

Two years after the St George’s High School was destroyed by a fire, the school was rebuilt and renamed the St George’s School of Sciences. Minister of Education Priya Manickchand on Monday visited ...

Since my last article, Gilead Sciences, Inc.'s stock price has continued to rise, thanks in part to strong sales of its HIV portfolio and an improved EBIT margin year-over-year. So, sales of the ...

Magrolimab is under clinical development by Gilead Sciences and currently in Phase I for Peritoneal Cancer. According to GlobalData, Phase I drugs for Peritoneal Cancer have an 85% phase transition ...

GS-0272 is under clinical development by Gilead Sciences and currently in Phase I for Rheumatoid Arthritis. According to GlobalData, Phase I drugs for Rheumatoid Arthritis have a 71% phase transition ...

Financial giants have made a conspicuous bearish move on Gilead Sciences. Our analysis of options history for Gilead Sciences GILD revealed 10 unusual trades. Delving into the details, we found 20 ...

The replays will be available for at least 30 days following the presentation. Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more ...